Skip to main content
. 2019 Aug 12;9:11632. doi: 10.1038/s41598-019-48064-w

Figure 5.

Figure 5

SPANXB1 depleted TNBC cells failed to achieve robust primary tumor growth and distant metastasis. (A) Markedly reduced (p = 0.0005–0.006) primary tumor growth of the SPANXB1-deficient MDA-MB-231 cells in vivo compared to the controls. (B) Low SPANXB1:SH3GL2 expression ratio in the SPANXB1-deficient primary TNBC tumors. (C) Reduced pulmonary metastasis of the SPANXB1-deficient TNBC cells compared to the controls. The number of metastatic lung nodules was lower in the SPANXB1-deficient mice group compared to the control groups. (D) Absence of visible or microscopic liver metastasis of the orthotopically implanted SPANXB1-deficient TNBC cells in the NSG mice. Control cells achieve extensive liver metastasis (arrows). CSi: Control SiRNA treated; KD: SPANXB1-SiRNA treated. Actin was used as a loading control (B). CSi: M: Mouse. CSi: Control SiRNA; KD: SPANXB1-SiRNA treated. Magnification X 200 (C). In Western blotting, all experimental and control antibodies were run in parallel for the same immunoblot. The Image J software (https://imagej.nih.gov/ij/) was used for Western blot quantification.